EGFR and non-small cell lung carcinoma: The FLAURA 2 trial evaluated osimertinib with or without chemotherapy in EGFR-mutated (exon 19 deletions or exon 21 L858R) advanced NSCLC and revealed longer systemic PFS in the combination arm versus the osimertinib alone arm among patients with baseline BMs (median PFS 24.9 m vs. 13.8 m; HR 0.47; 95% CI 0.33–0.66) [32].